Wexford Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Wexford Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,500	Closed	-$840K	–	289
2025 Q1	$840K	Sell	21,500 -2,500	-10%	-$108K	0.22%	87
2024 Q4	$1.3M	Buy	24,000 +10,000	+71%	+$511K	0.21%	60
2024 Q3	$706K	Hold	14,000	–	–	0.17%	86
2024 Q2	$616K	Buy	+14,000	New	+$593K	0.16%	94

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wexford Capital's MLTX Position: Q2 2025 in Review

Wexford Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 21,500 shares — an estimated $840K sold.

Wexford Capital first reported a position in MLTX in Q2 2024 and held it in 4 quarters. The position peaked at $1.3M in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

Wexford Capital reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
Wexford Capital sold 21,500 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $840K.
Wexford Capital first reported a position in MoonLake Immunotherapeutics in Q2 2024 and held it in 4 quarters.
Wexford Capital's MoonLake Immunotherapeutics position peaked at $1.3M in Q4 2024.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.